 Braxia Scientific Corp CSE:BRAX OTC: BRAXF, a Toronto-based company that provides ketamine-assisted therapy announced that CEO Dr. Roger McIntyre and Chief Medical and Scientific Officer Dr. Josh Rosenblat have received funding of CA918.000 approximately 732.000 from the Canadian Institutes of Health Research. The grant will be used for a clinical trial that will assess the effectiveness of intravenous ketamine in combination with Internet-based cognitive behavioural therapy in the treatment of suicidality in persons with depression. 